Raymond James Financial Services Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Raymond James Financial Services Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-750	Closed	-$37.1K	–	3251
2023 Q1	$37.1K	Buy	+750	New	+$21.8K	﹤0.01%	3146
2022 Q4	–	Sell	-763	Closed	-$51K	–	3266
2022 Q3	$51K	Sell	763 -20	-3%	-$1K	﹤0.01%	3086
2022 Q2	$32K	Sell	783 -19	-2%	-$856	﹤0.01%	3125
2022 Q1	$40K	Hold	802	–	–	﹤0.01%	3212
2021 Q4	$48K	Sell	802 -47	-6%	-$2.31K	﹤0.01%	3192
2021 Q3	$42K	Sell	849 -16	-2%	-$842	﹤0.01%	3198
2021 Q2	$49K	Sell	865 -18	-2%	-$962	﹤0.01%	3210
2021 Q1	$51K	Buy	883 +92	+12%	+$6.95K	﹤0.01%	3099
2020 Q4	$54K	Buy	+791	New	+$108K	﹤0.01%	2909

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Raymond James Financial Services Advisors's BCLI Position: Q2 2023 in Review

Raymond James Financial Services Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2023, closing a stake of 750 shares — an estimated $37.1K sold.

Raymond James Financial Services Advisors first reported a position in BCLI in Q4 2020 and held it in 9 quarters. The position peaked at $54K in Q4 2020. 58 funds tracked by Wall St. Rank hold BCLI as of Q2 2023.

Raymond James Financial Services Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 750 BRAINSTORM CELL THERAPUTC shares in Q2 2023, an estimated $37.1K.
Raymond James Financial Services Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 9 quarters.
Raymond James Financial Services Advisors's BRAINSTORM CELL THERAPUTC position peaked at $54K in Q4 2020.
58 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2023, filed 25 Jul 2023.